Global capacity CSL Seqirus operates manufacturing plants in the United States, United Kingdom, Germany and Australia, providing a transcontinental footprint and substantial capacity to support reliable vaccine supply across multiple markets and align with pandemic preparedness programs.

Vaccine Innovation The company is advancing cell-based and adjuvanted influenza vaccines and exploring avian influenza and RNA-based approaches, presenting opportunities to partner on next generation vaccines, stockpiling programs and payer value propositions.

Public Partnerships Recent collaborations with government health agencies and ongoing pandemic preparedness initiatives indicate established procurement channels for tenders and stockpiling programs, offering pathways to large, long-term vaccine supply agreements.

Market Position As a leading influenza vaccine player with a broad geographic footprint and a portfolio that includes vaccines of national significance, CSL Seqirus is well positioned to expand adoption through regional immunization programs and strategic partnerships.

Commercial Readiness A data driven value proposition supported by clinical and economic studies can enhance market access and payer engagement, creating opportunities to accelerate uptake in both public sector programs and private markets as demand for influenza vaccines grows.